Avellino Labs

Granular corneal dystrophy is an eye condition affecting about one in a thousand people with no current cure. Early diagnosis can help with prevention and warn patients when not to have LASIK and other corneal surgeries, resulting in protein formations in the eye and vision loss. Avellino Lab's proprietary and patented DNA sequencing test detects an individual's risk for this genetic condition. Avellino is also working on tests for other rare ophthalmic diseases which can lead to vision loss.

Avellino Labs provides eye care professionals a rapid and inexpensive screening test to further ensure patients cleared for refractive surgery are good candidates. We test for multiple single point gene mutations associated with the most common types of corneal dystrophy, a condition that may not effect vision until triggered by refractive surgery.


Type
Private
HQ
Menlo Park, US
Founded
2012
Employees
9 (est)
Avellino Labs was founded in 2012 and is headquartered in Menlo Park, US

Avellino Labs Locations

Menlo Park, US

Avellino Labs Metrics

Avellino Labs Summary

Founding Date

2012

Avellino Labs Online Presence

Avellino Labs News

Avellino Labs Company Life